Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Dvorak

Showing results (51-60 of 222) with videos related to

Pageof 23
Sort By:
Pediatric Blood & Cancer|November 22, 2011
Antifungal prophylaxis in pediatric hematology/oncology: new choices & new dataChristopher C Dvorak, Brian T Fisher, Lillian Sung, et al.
Pediatric Transplantation|July 1, 2014
A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiencyChristopher C Dvorak, Biljana N Horn, Jennifer M Puck, et al.
Human Immunology|April 6, 2011
Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplantsShalini Pereira, Tamara Vayntrub, Debra D Hiraki, et al.
Frontiers in Pharmacology|July 28, 2020
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) PopulationPraveen Shukla, Srijib Goswami, Ron J Keizer, et al.
Frontiers in Pediatrics|August 5, 2021
A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young AdultsBeth Apsel Winger, Susie E Long, Jordan Brooks, et al.
Journal of Clinical Pharmacology|January 20, 2022
Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell TransplantationShuhui Li, Christopher C Dvorak, Ying Lu, et al.
The Pediatric Infectious Disease Journal|September 30, 2015
Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant PopulationEmily R Levy, Lisa Musick, Matthew S Zinter, et al.
Journal of Pediatric Hematology/Oncology|March 1, 2014
Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literatureErin E Karski, Christopher C Dvorak, Wing Leung, et al.
Pediatric Blood & Cancer|July 27, 2019
Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemiaAnna Hecht, Julia Meyer, Farid F Chehab, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2012
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitutionJason Law, Morton J Cowan, Christopher C Dvorak, et al.
Pageof 23

Showing results (51-60 of 222) with videos related to

Sort By:
Pageof 23
Pediatric Blood & Cancer|November 22, 2011
Antifungal prophylaxis in pediatric hematology/oncology: new choices & new dataChristopher C Dvorak, Brian T Fisher, Lillian Sung, et al.
Pediatric Transplantation|July 1, 2014
A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiencyChristopher C Dvorak, Biljana N Horn, Jennifer M Puck, et al.
Human Immunology|April 6, 2011
Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplantsShalini Pereira, Tamara Vayntrub, Debra D Hiraki, et al.
Frontiers in Pharmacology|July 28, 2020
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) PopulationPraveen Shukla, Srijib Goswami, Ron J Keizer, et al.
Frontiers in Pediatrics|August 5, 2021
A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young AdultsBeth Apsel Winger, Susie E Long, Jordan Brooks, et al.
Journal of Clinical Pharmacology|January 20, 2022
Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell TransplantationShuhui Li, Christopher C Dvorak, Ying Lu, et al.
The Pediatric Infectious Disease Journal|September 30, 2015
Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant PopulationEmily R Levy, Lisa Musick, Matthew S Zinter, et al.
Journal of Pediatric Hematology/Oncology|March 1, 2014
Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literatureErin E Karski, Christopher C Dvorak, Wing Leung, et al.
Pediatric Blood & Cancer|July 27, 2019
Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemiaAnna Hecht, Julia Meyer, Farid F Chehab, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2012
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitutionJason Law, Morton J Cowan, Christopher C Dvorak, et al.
Pageof 23